

Gastric acid suppressants—too much of a good thing?

Ian C. Logan^{1,*}, Deepa Sumukadas^{1,2} and Miles D. Witham^{1,2}
 * To whom correspondence should be addressed.

Received March 1, 2010.

Key words proton pump inhibitors • side effects • pneumonia • enteric infection • hypomagnesaemia • gastric acid

Gastric acid suppressants, in the form of histamine-2 receptor antagonists (H2RAs) and subsequently proton pump inhibitors (PPIs), have transformed the management of dyspepsia, peptic ulceration and gastro-oesophageal reflux disease. PPIs are now among the most commonly prescribed medications worldwide. In the United Kingdom, PPIs accounted for 34 million prescriptions worth £192 million in the year to June 2009 [1], and \$26.5 billion was spent globally on PPIs in 2008 [2]. A large number of patients—as many as 90% in one study [3]—are taking these drugs with no appropriate guideline-based indication. Whilst PPIs and H2RAs are considered by most prescribers to be both effective and safe, their side-effect profile may be less benign in older people than has been hitherto realised.

Several of the adverse effects of gastric acid suppressants that have been documented are pertinent to older people. Observational studies show an association between the use of gastric acid suppressants and community-acquired pneumonia (CAP). Several studies have shown that current PPI use, particularly if started recently, is associated with an increased risk of CAP [4, 5]. The studies did not consistently observe an association with H2RAs, perhaps because of their weaker acid suppressant activity. One study examining cardiothoracic surgery patients taking stress ulcer prophylaxis found pantoprazole, but not ranitidine, was associated with an increased risk of hospital-acquired pneumonia [6]. It has been suggested that losing the non-specific defence of a gastric pH below 4 results in more gut flora residing in the upper gastrointestinal (GI) tract [4], and the more powerful acid suppressant effects of PPIs would therefore be expected to be more strongly linked with pneumonia, as is observed.

There is also a significant body of observational evidence linking gastric acid suppression to enteric infection. A systematic review published in 2007 [7] reported an increased risk of *Salmonella* and *Campylobacter* infection in those using gastric acid suppressants (odds ratio, OR 2.55; 95% confidence interval, 95% CI 1.53–4.26). The association was greater with PPIs (OR 3.33, 95% CI 1.84–6.02) than H2RAs, but remained significant for H2RAs (OR 2.03, 95% CI 1.05–3.92). Gastric acid suppression is associated with colonisation of the normally sterile upper GI tract [8]; acid suppression may therefore remove an important physiological barrier, allowing orally ingested enteric pathogens to reach the gut.

Perhaps most importantly for older people, acid suppression may also be associated with an increased risk of *Clostridium difficile*-associated disease (CDAD). Although some studies did not find an association between PPIs and CDAD, a number of other studies have demonstrated that PPI use increases the risk of developing CDAD in both hospitalised and community-dwelling patients, with a meta-analysis [7] reporting a significant increase in risk (OR 1.96, 95% CI 1.28–3.00). A weaker association appears to exist for H2RA use [9]. Patients treated for CDAD are more likely to have a recurrence if they remain on PPI therapy [8].

There are other potentially adverse effects of gastric acid suppressants that are relevant to the health of older people. A number of case reports have suggested a relationship between PPIs and microscopic colitis, a condition now increasingly recognised as a cause of chronic watery diarrhoea in older people. Severe hypomagnesaemia resistant to magnesium replacement but resolving on withdrawal of PPI has been reported, especially in older people [10]. This can be partially corrected by high-dose oral magnesium supplement, suggesting that PPIs inhibit the active transport mechanism of intestinal magnesium absorption [10]. Low serum magnesium levels have been shown to be associated with adverse prognosis and increased mortality in various settings [11] and have been found to independently correlate with muscle performance in older people [12].

The change in gastric acidity with consequent changes in drug absorption has been blamed for malabsorption of nutrients including iron, vitamin B12 and many of the drug interactions with PPIs. Although this has not been of major clinical concern, the recent controversy surrounding concomitant use of PPIs and clopidogrel serves as a reminder that this class of drugs is not without the risk of interactions [13]. Finally, some recent studies have suggested an association between PPI use and increased risk of osteoporotic fracture [14], although this association does not appear to be consistent across all populations.

What should we do about these observations? There is no doubt that gastric acid suppressants are important drugs with a crucial role in the management of a number of GI diseases, and care is needed to ensure that patients taking these agents for good indications do not have their prescriptions stopped. However, there is good evidence that they are frequently being prescribed for non-specific and inappropriate reasons, and that a large number of patients are taking these agents for much longer than necessary [15]. It is unlikely that large randomised controlled trials in older people will be performed to give definitive evidence on the risk-benefit ratio in older people taking these agents, but it would seem sensible to redouble our efforts to stop these agents in patients with previous dyspepsia but no endoscopic disease or gastric irritant use. By reducing the dose gradually over a period of a few weeks any impact of rebound acid secretion, and hence symptoms, should be minimised. Not only would this reduce the burden of medication and potentially protect against major infective illnesses, it would also free up significant amounts of money in these strained times to be reinvested in health interventions of proven benefit to older people.

Key points

- Considerable resources are spent on inappropriately prescribed gastric acid suppressants.
- PPIs are associated with an increased risk of CAP.
- Gastric acid suppression is associated with an increased risk of enteric infection.
- PPIs are associated with a variety of other forms of ill health in older people.

Conflicts of interest

No external funding was used to support this work, but Dr Sumukadas is a co-grant holder on a British Geriatrics Society Specialist Registrar Research start-up grant (01/2009) examining the relationship between PPI use and hypomagnesaemia. Dr Witham is funded by the Chief Scientist Office, Scottish Government as a Clinician Scientist.

© The Author 2010. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

References

1. NHS Business Services Authority. Update on Growth in Prescription Volume and Cost in the Year to June 2009. http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/Volume_and_cost_year_to_June_2009.pdf (14 February 2010, date last accessed).
2. IMS Top-Line Industry Data. Top 15 Global Therapeutic Classes 2008. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/StaticFile/Top_Line_Data/Global_Top_15_Therapy_Classes.pdf (14 February 2010, date last accessed).
3. Pham QC, Regal RE, Bostwick TR, Knauf KS. Acid suppressive therapy use on an inpatient internal medicine service. *Ann Pharmacother* 2006;40:1261–6. [» Abstract/FREE Full Text](#)
4. Laheij RJF, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. *JAMA* 2004;292:1955–60. [» Abstract/FREE Full Text](#)
5. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia. A population-based case-control study. *Arch Intern Med* 2007;167:950–5. [» Abstract/FREE Full Text](#)
6. Miano TA, Reichert MG, Houle TT, MacGregor DA, Kincaid EH, Bowton DL. Nosocomial pneumonia risk and stress ulcer prophylaxis: a comparison of pantoprazole vs ranitidine in cardiothoracic surgery patients. *Chest* 2009;136:440–7. [» Abstract/FREE Full Text](#)
7. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* 2007;102:2047–56. [» CrossRef » Medline » Web of Science](#)
8. Cadle RM, Mansouri MD, Logan N, Kudva DR, Musher DM. Association of proton pump inhibitors with outcomes in *Clostridium difficile* colitis. *Am J Health Syst Pharm* 2007;64:2359–63. [» Abstract/FREE Full Text](#)
9. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid suppressive agents and the risk of community-acquired *Clostridium difficile*-associated disease. *JAMA* 2005;294:2989–95. [» Abstract/FREE Full Text](#)
10. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. *Clin Endocrinol (Oxf)* 2008;69:338–41. [» CrossRef » Medline](#)
11. Haglin L, Tornkvist B, Backman L. Prediction of all-cause mortality in a patient population with hypertension and type 2 DM by using traditional risk factors and serum-phosphate, -calcium and -magnesium. *Acta Diabetol* 2007;44:138–43. [» CrossRef » Medline » Web of Science](#)
12. Dominguez LJ, Barbagallo M, Lauretani F, et al. Magnesium and muscle performance in older persons: the InCHIANTI study. *Am J Clin Nutr* 2006;84:419–26. [» Abstract/FREE Full Text](#)
13. Last EJ, Sheehan AH. Review of recent evidence: potential interactions between clopidogrel and proton pump inhibitors. *Am J Health Syst Pharm* 2009;66:2117–22. [» Abstract/FREE Full Text](#)
14. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. *Calcif Tissue Int* 2009;84:13–9. [» CrossRef » Medline » Web of Science](#)
15. Naunton M, Peterson GM, Bleasel MD. Overuse of proton pump inhibitors. *J Clin Pharm Ther* 2000;25:333–40. [» CrossRef » Medline » Web of Science](#)

« Previous | Next Article »
[Table of Contents](#)

This Article
 Age Ageing (2010) 39 (4): 410–411.
 doi: 10.1093/ageing/afq057
 First published online: May 26, 2010

Extract
 » Full Text (HTML)
 Full Text (PDF)

All Versions of this Article:
 afq057v1
 39/4/410 **most recent**

Classifications

Editorial

Services

- Alert me when cited
- Alert me if corrected
- Alert me if commented
- Find similar articles
- Similar articles in PubMed
- Add to my archive
- Download citation
- Request Permissions
- Disclaimer

Responses

Citing Articles

Google Scholar

PubMed

Share

Navigate This Article

- Top
- Key points
- Conflicts of interest
- References

People also read [Beta]

- Overuse and inappropriate prescribing of proton pump inhibitors in patients with *Clostridium difficile*-associated disease
- Elderly medicine: a training guide

What's this?

Search this journal:

Advanced »

Current Issue

January 2012 41 (1)



Alert me to new issues

The Journal

About this journal
 Publishers' Books for Review



Read E-letters
 Rights & Permissions
 Dispatch date of the next issue
 The journal is a member of the Committee on Publication Ethics (COPE)

C O P E COMMITTEE ON PUBLICATION ETHICS

We are mobile – find out more

Useful Links

Useful Links

Published on behalf of

The British Geriatrics Society


Impact factor: 2.719
5-Yr impact factor: 3.202

Editor-in-Chief
Professor Roger Francis

View full editorial board

For Authors

Instructions to authors
 Author Self Archiving Policy



Open Access options for authors – visit Oxford Open

Online Submission
 Submit a manuscript
 Online Submission Instructions



This journal enables compliance with the NIH Public Access Policy

Alerting Services

- Email table of contents
- Email Advance Access
- CiteTrack
- XML RSS feed

Corporate Services

Advertising sales
 Reprints
 Supplements

Most Read Most Cited

- » Their last 6 months: suffering and survival of end-stage dementia patients
- » The clock-drawing test
- » STOPP (Screening Tool of Older Persons' potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers' criteria
- » Sexual Desire, Erection, Orgasm and Ejaculatory Functions and Their Importance to Elderly Swedish Men: A Population-based Study
- » Iron deficiency anaemia in older people: investigation, management and treatment
- » View all Most Read articles